Persistence of Hepatitis A Antibody in Healthy Adults ~32 Years Post Vaccination.

Best Healthcare Inc.300 enrolled

Overview

The goal of this clinical trial is to evaluate the persistence of Hepatitis A antibody \~32 years post vaccination in healthy adults. The questions this study will answer are: 1) how long antibody persists and 2) The immune response to an additional dose of vaccine among those with no detectable antibody. Participants will be asked to provide a blood specimen. Those with no detectable antibody will be offered an additional dose of vaccine. The kinetics of antibody response in this population will be summarized.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

300

Conditions

Hepatitis A

Interventions

Hepatitis A VaccineBIOLOGICAL

Hepatitis A Vaccine

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Consent obtained * Participated in original hepatitis A study in 1991 * No detectable hepatitis A antibody \~32 years after study start Exclusion Criteria: * Receipt of any dose of hepatitis A vaccine other than the hepatitis A vaccine used in the initial studies * History of hepatitis A * Receipt of blood transfusion or blood products, including immunoglobulins, within the past 6 months. * Receipt of any vaccine within the 14 days before receipt of the additional dose of hepatitis A vaccine or scheduled to receive any vaccine within 30 days after receipt of a booster dose of vaccine.

Outcomes

Primary Outcomes

Persistence of Antibody

Hepatitis A antibody

Time frame: 32 Years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.